BR0210510A - Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo - Google Patents

Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo

Info

Publication number
BR0210510A
BR0210510A BR0210510-1A BR0210510A BR0210510A BR 0210510 A BR0210510 A BR 0210510A BR 0210510 A BR0210510 A BR 0210510A BR 0210510 A BR0210510 A BR 0210510A
Authority
BR
Brazil
Prior art keywords
group
lower alkyl
alkoxy
nitrogen
substituted
Prior art date
Application number
BR0210510-1A
Other languages
English (en)
Inventor
Toshihiro Nishimura
Hideki Fujikura
Nobuhiko Fushimi
Kazuya Tatani
Kenji Katsuno
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR0210510A publication Critical patent/BR0210510A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADO HETEROCìCLICO CONTENDO NITROGêNIO, COMPOSIçãO MEDICINAL CONTENDO O MESMO, USO MéDICO DO MESMO E INTERMEDIáRIO PARA O MESMO". A presente invenção propõe derivados heterocíclicos contendo nitrogênio representados pela fórmula geral: em que X^ 1^ e X^ 3^ representam independentemente N ou CH; X^ 2^ representa N ou CR^ 2^; X^ 4^ representa N ou CR^ 3^; e desde que um ou dois dos X^ l^, X^ 2^, X^ 3^ e X^ 4^ representem N; R^ 1^ representa um átomo de hidrogênio, um átomo de halogênio, um grupamento alquila inferior, um grupamento alcóxi inferior, um grupamento alquiltio inferior, um grupamento (alquila inferior) substituído por alcóxi inferior, um grupamento (alcóxi inferior) substituido por alcóxi inferior, um grupamento (alquila inferior) substituído por um (alcóxi inferior substituído por alcóxi inferior), um grupamento cíclico alquila inferior, um grupamento halo (alquila inferior) ou um grupamento representado pela fórmula geral: HO-A- em que A representa um grupamento alquileno inferior, um grupamento alquilenóxi inferior ou um grupamento alquileno-tio inferior; R^ 2^ representa um átomo de hidrogênio, um átomo de halogênio, um grupamento alquila inferior, um grupamento alquila inferior cíclico, um grupamento alcóxi inferior, um grupamento amino, um grupamento (acil inferior)amino , um grupamento mono(alquil inferior)amino ou um grupamento di(alquil inferior)amino; e R^ 3^ representa um átomo de hidrogênio ou um grupamento alquila inferior, ou sais seus aceitáveis do ponto de vista farmacêutico, ou promedicamentos seus, que são úteis como agentes para a prevenção ou tratamento de uma doença associada com hiperglicemia tal como diabetes, complicações diabéticas ou obesidade, composições farmacêuticas compreendendo os mesmos, e empregos farmacêuticos e produção de intermediários para os mesmos.
BR0210510-1A 2001-06-20 2002-06-17 Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo BR0210510A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001187368 2001-06-20
PCT/JP2002/006000 WO2003000712A1 (fr) 2001-06-20 2002-06-17 Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe

Publications (1)

Publication Number Publication Date
BR0210510A true BR0210510A (pt) 2005-01-11

Family

ID=19026665

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210510-1A BR0210510A (pt) 2001-06-20 2002-06-17 Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo

Country Status (9)

Country Link
US (1) US7271153B2 (pt)
EP (1) EP1405859A4 (pt)
JP (1) JP4399254B2 (pt)
KR (1) KR100882179B1 (pt)
CN (1) CN100376592C (pt)
BR (1) BR0210510A (pt)
CA (1) CA2455300A1 (pt)
HK (1) HK1068895A1 (pt)
WO (1) WO2003000712A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
JP4399254B2 (ja) * 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004058790A1 (ja) * 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003902263A0 (en) * 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
CA2549022A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2005012318A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
RS20060320A (en) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
WO2005085265A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2579716A1 (en) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20110288A1 (es) * 2008-08-28 2011-05-26 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
DK2488515T3 (en) * 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
PT2697218T (pt) 2011-04-13 2016-07-13 Janssen Pharmaceutica Nv Processo para preparação de compostos úteis como inibidores da sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
BR112015022441B1 (pt) 2013-03-14 2021-12-07 Mars, Incorporated Composição de sabor que contém glicosídeos de hmg
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149818C (da) 1976-10-28 1987-04-06 Sankyo Co Analogifremgangsmaade til fremstilling af 5-fluoruracil-derivater
JPS53135987A (en) 1977-04-15 1978-11-28 Sankyo Co Ltd 5-fluorouracil derivative
JPS53144582A (en) 1977-05-20 1978-12-15 Sankyo Co Ltd 5-fluorouracil derivatives
US4248999A (en) * 1976-10-28 1981-02-03 Sankyo Company Limited 5-Fluorouracil derivatives and process for preparing thereof
JP3994461B2 (ja) * 1996-12-27 2007-10-17 和光純薬工業株式会社 ヒドロキシアルキルピリジン誘導体
JP2000044589A (ja) * 1998-08-03 2000-02-15 Kikkoman Corp マルトオリゴ糖誘導体及びその用途
RU2232767C2 (ru) * 1999-08-31 2004-07-20 Киссеи Фармасьютикал Ко., Лтд. Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
JP4399254B2 (ja) * 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体

Also Published As

Publication number Publication date
WO2003000712A1 (fr) 2003-01-03
CN100376592C (zh) 2008-03-26
CA2455300A1 (en) 2003-01-03
JPWO2003000712A1 (ja) 2005-04-21
CN1537114A (zh) 2004-10-13
KR20040010723A (ko) 2004-01-31
US7271153B2 (en) 2007-09-18
KR100882179B1 (ko) 2009-02-06
US20050049203A1 (en) 2005-03-03
EP1405859A1 (en) 2004-04-07
HK1068895A1 (en) 2005-05-06
JP4399254B2 (ja) 2010-01-13
EP1405859A4 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
BR0210510A (pt) Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo
NO20020968L (no) Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
EP1609798A4 (en) CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
BR0307576A (pt) Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos
BRPI0508243A (pt) derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
TW200637869A (en) The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
BR0314383A (pt) Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0212069A (pt) Agentes antidiabéticos orais
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
BR0206552A (pt) Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BR0214937A (pt) Processo de preparação de derivados de equinocandina
BR0315106A (pt) Derivados antimicrobianos de [3.1.0]oxazolidinona bicìclica
BR0312176A (pt) Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.